基于数据挖掘探讨吕文良教授治疗自身免疫性肝病的用药规律

doi:10.20047/j.issn1673-7210.2023.15.01

Abstract
Figure/Table
References (34)
Related Citation (15)

Download: PDF (2063 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the medication rules and academic thoughts of Professor Lü Wenliang’s treatment of autoimmune liver disease, through sorting out the medical records of Professor Lü Wenliang’s treatment of autoimmune liver disease, based on the data mining. Methods The outpatient medical record information of Professor Lü Wenliang from January 1, 2019 to January 1, 2022 was retrieved through the Information Center of Guang’anmen Hospital, China Academy of Chinese Medical Sciences, the patients diagnosed with autoimmune liver disease by Western medicine were screened, and the information of diagnosis and prescription of traditional Chinese and western medicine was extracted. Excel 2016 was used to standardize the prescription information into a database. Traditional Chinese medicine inheritance computing platform V 3.0 and R language (R 4.2.1) were used to calculate the distribution rules of drug use frequency, efficacy, four qi, five flavor, and meridian conversion, then the rule of formulation and cluster analysis were carried out. Results A total of 658 prescriptions and 158 traditional Chinese medicines were sorted out by inclusion and exclusion standard screening. The analysis of the rule of drug use showed that the four qi of the traditional Chinese medicine were mainly warm, cold, and flat; the five flavors are mainly bitter, sweet, and hot, the main channels are liver, spleen, lung, and stomach. The drug effect is mainly to supplement deficiency class, clearing heat class, and digestion class. In terms of the frequency of drug use, the top five drugs were Astragalus, Paeony, Hawthorn, Scutellaria, and Coptis chinensis. Association rule analysis showed that Astragalus-Paeony was the most frequently used antidrug. The prescriptions can be divided into four clusters by K-means clustering algorithm, and the core prescription drugs can be obtained. Conclusion Professor Lü Wenliang’s prescription for the treatment of autoimmune liver disease has distinct medication rules. The treatment is based on the principle of “invigorating qi and blood, softening the liver and strengthening the spleen, clearing heat and removing dampness”. The medication pays attention to the harmonization of qi and blood, matching cold and temperature, lifting and lowering of qi and supplementing both. It provides a reference for the diagnosis and treatment of autoimmune liver diseases.

Key words： Autoimmune liver disease Lü Wenliang Traditional Chinese medicine inheritance computing platform V 3.0 R language Prescription mining Medication rule

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAO Ziang ZHAO Xin LYU Wenliang ZHANG Lili QIANG Rui

Cite this article:

YAO Ziang ZHAO Xin LYU Wenliang ZHANG Lili QIANG Rui. Medication rule of Professor Lü Wenliang in treating autoimmune liver disease based on data mining[J]. 中国医药导报, 2023, 20(15): 4-11.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.15.01 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I15/4

[1] 郭长存，时永全，尚玉龙，等.原发性硬化性胆管炎诊断及治疗指南（2021）[J].临床肝胆病杂志，2022，38（1）：50- 61.
[2] 中国医师协会风湿免疫科医师分会自身抗体检测专业委员会，国家风湿病数据中心，国家皮肤与免疫疾病临床医学研究中心.自身免疫性肝病相关自身抗体检测的临床应用专家共识[J].中华内科杂志，2021，60（7）：619- 625.
[3] 尤红，段维佳，李淑香，等.原发性胆汁性胆管炎的诊断和治疗指南（2021）[J].临床肝胆病杂志，2022，38（1）：35-41.
[4] Tanaka A，Mori M，Matsumoto K，et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis，autoimmune hepatitis，and primary sclerosing cholangitis in Japan [J]. Hepatol Res，2019，49（8）：881- 889.
[5] 李尧，徐晓欧.自身免疫性肝病的发病机制及诊疗进展[J].医学综述，2021，40（9）：194-198.
[6] 幸鹭，刘成海.病证结合诊治自身免疫性肝病[J].中西医结合肝病杂志，2021，31（4）：299-302.
[7] 朱步坤，李刚，张玮.中西医药治疗自身免疫性肝病研究进展[J].实用肝脏病杂志，2020，23（3）：453-456.
[8] 包一珺，吕文良，强睿，等.基于肠道菌群与抑木扶土理论探讨自身免疫性肝病的病机与治疗[J/OL].辽宁中医杂志：1-8[2022-09-01].http：//kns.cnki.net/kcms/detail/21.1128.R.20220614.1202.026.html.
[9] 佚名.自身免疫性肝病诊断和治疗指南[J].中华风湿病学杂志，2011，15（8）：556-558.
[10] 国家药典委员会编.中华人民共和国药典[S].一部.北京：中国医药科技出版社，2020.
[11] 国家中医药管理局.中华本草[M].上海：上海科学技术出版社，2005.
[12] 高学敏.中药学（供中医药类专业用）[M].北京：中国中医药出版社，2002.
[13] 卢朋，李健，唐仕欢，等.中医传承辅助系统软件开发与应用[J].中国实验方剂学杂志，2012，18（9）：1-4.
[14] 唐仕欢，杨洪军.中医组方用药规律研究进展述评[J].中国实验方剂学杂志，2013，19（5）：359-363.
[15] 唐仕欢，申丹，卢朋，等.中医传承辅助平台应用评述[J].中华中医药杂志，2015，30（2）：329-331.
[16] 张静雅，曹煌，许浚，等.中药苦味药性表达及在临证配伍中的应用[J].中草药，2016，47（2）：187-193.
[17] 张静雅，曹煌，龚苏晓，等.中药甘味的药性表达及在临证配伍中的应用[J].中草药，2016，47（4）：533-539.
[18] 孙玉平，张铁军，曹煌，等.中药辛味药性表达及在临证配伍中的应用[J].中草药，2015，17（6）：187-188.
[19] （清）叶桂撰.本草经解[M].北京：学苑出版社，2011.
[20] Onofrio FQ，Hirschfield GM，Gulamhusein AF. A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist [J]. Gastroenterol Hepatol （NY），2019，15（3）：145- 154.
[21] （梁）陶弘景，原坡撰.本草经集注卷4草木中[M].北京：学院出版社，2013.
[22] 清·黄元御著.玉楸药解[M].北京：中国医药科技出版社，2017.
[23] 靳华，李秀惠，尹玲，等.钱英教授治疗自身免疫性肝炎经验[J].中西医结合肝病杂志，2022，32（4）：298-300.
[24] 马天驰，王彩霞，于漫.论《景岳全书》调脾胃养生思想[J].中华中医药学刊，2016，34（6）：1313-1316.
[25] 郭霭春.黄帝内经素问校注[M].北京：中国中医药出版社，2020.
[26] 杨曼芩，范伏元.浅析从肝治肺[J].中医药临床杂志，2021，33（4）：660-663.
[27] 杨倩，朱红梅，王勤英.自身免疫性肝病诊治进展[J].中国药物与临床，2020，20（18）：3026-3029.
[28] 魏雨石，张明香，田霞.基于治未病思想探讨茵芪三黄解毒汤对慢性乙型肝炎的作用机制[J].云南中医中药杂志，2021，42（3）：38-41.
[29] 王琦，张明香，孙胜男.茵芪三黄解毒汤治疗乙肝肝纤维化疗效机制的理论探讨[J].实用中医内科杂志，2021， 35（3）：12-15.
[30] 魏超，江鸿，邓先桂，等.茵芪三黄解毒汤联合常规西医治疗慢性乙型肝炎肝胆湿热证患者的疗效观察[J].实用临床医药杂志，2021，25（9）：37-40，51.
[31] 强睿，吕文良.基于“肝体阴用阳”浅析五脏皆体阴用阳[J].环球中医药，2022，15（1）：96-99.
[32] 强睿，吕文良，姚子昂，等.吕文良“三黄”组合思路在肝病中的应用[J].世界中西医结合杂志，2022，17（3）：617-621.
[33] 曹正民，吕文良，汪青楠.吕文良教授以“调和气血”治疗肝纤维化经验[J].时珍国医国药，2021，32（5）：1236-1238.
[34] 赵鑫，徐蕾，武庆娟，等.“和法”在慢性乙型病毒性肝炎治疗中的应用[J].北京中医药，2021，40（11）：1233-1237.